Premium
Brain metastasis from colorectal cancer: Prognostic factors and survival
Author(s) -
Noura Shingo,
Ohue Masayuki,
Shingai Tatsushi,
Fujiwara Ayako,
Imada Shinya,
Sueda Toshinori,
Yamada Terumasa,
Fujiwara Yoshiyuki,
Ohigashi Hiroaki,
Yano Masahiko,
Ishikawa Osamu
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23055
Subject(s) - medicine , colorectal cancer , brain metastasis , incidence (geometry) , metastasis , radiation therapy , oncology , cancer , overall survival , surgery , gastroenterology , physics , optics
Background Colorectal cancer (CRC) rarely metastasizes to the brain, and the incidence rate has been reported to be 1–2%. Unfortunately, the median survival for patients with brain metastasis (BM) from CRC is short. In this study, we retrospectively investigated the BM from CRC and examined the prognostic factors. Methods We retrospectively analyzed 29 CRC patients who developed BM; the lesions were diagnosed synchronously in 1 patient and metachronously in 28 patients. Results After BM, the median survival time was 7.4 months. In the groups of patients who underwent surgical resection and radiation therapy, the median survival times were 8.3 and 7.4 months, respectively. The difference between the two groups was not statistically significant. The curability of the therapy for BM, number of BM, number of metastatic organs including the brain, and the CEA level at the time of treatment of the BM were significantly associated with the cancer‐specific survival ( P = 0.0044, 0.0229, 0.0019, and 0.0205, respectively). Conclusions The prognosis of patients with BM from CRC was associated with the curability of the therapy for BM, number of metastatic organs, and the serum CEA level. The modality of treatment had no significant impact on the outcome. J. Surg. Oncol. 2012; 106:144–148. © 2012 Wiley Periodicals, Inc.